Azelis Raises €1.7 Billion in Brussels IPO

Belgian-headquartered multinational distributor Azelis and its shareholders have raised €1.77 billion in an initial public offering (IPO) on the Euronext Brussels exchange. Azelis gets €880 million from the offering, while shareholders including private equity firm EQT and PSP Investments receive €891 million.

Shares were offered on Sept. 16 at €26 each, the top end of its previously announced range of €22-26 per share, valuing the company at €6.1 billion. Azelis said the offer was oversubscribed multiple times. Consequently, it closed the offer period on Sept. 16, ahead of its expected close on Sept. 21.

"We are delighted to have successfully priced our IPO, an important step in our ambition to be the preeminent global innovation service provider for the specialty chemicals and food ingredients distribution market,” said CEO Hans Joachim Müller.

The significant raise, Müller said, will enable Azelis to continue investing in growth and strengthen its position as an international market leader. "I am extremely proud that we have been able to secure investment from such high-quality international institutions. This is a very exciting moment for us as we embark on the next stage of our journey."

Together with borrowings under new credit facilities, Azelis plans to use the money to pay down debt and fund acquisitions.

The IPO was the biggest in Brussels since 2007, when multi-metals manufacturer Nyrstar went public, according to data compiled by Bloomberg.

Author: Elaine Burridge, Freelance Journalist

Belgian-headquartered multinational distributor Azelis has raised €1.77...
Belgian-headquartered multinational distributor Azelis has raised €1.77 billion in an initial public offering (IPO) on the Euronext Brussels exchange. Shares, which were oversubscribed multiple times, were offered at €26 each on Sept. 16, valuing the company at €6.1 billion. (c) Azelis

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.